Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis

Table 4

Result of sensitivity analysis.

Variable	Patients (rifaximin/control)	Pooled RR	𝑃
All in Europe [24–29]	231 (113/118)	3.16 [0.92, 10.93]	0.07
Acute HE [21, 27, 30]	157 (82/75)	0.77 [0.20, 2.93]	0.70
Chronic HE [26, 28, 29]	107 (54/53)	7.6 [1.87, 30.78]	0.005

HE: hepatic encephalopathy; control lactulose or lactitol; RR: relative risk.